Fonterra says it has $1 billion available for debt reduction after completing its latest asset sale

Fonterra says it has $1 billion available for debt reduction after completing its latest asset sale

Fonterra says it has agreed the sale of its 50% share of DFE Pharma for $633 million.

It says the cash from this sale, along with proceeds from its other asset sales across the year (including $380 million received for the Tip Top ice cream business) will give it over $1 billion available for debt reduction.

The announcement of the sale on Wednesday came a day before the struggling dairy co-operative is to announce its financial results for the year to July.

Fonterra confirmed on Wednesday that the DFE Pharma sale would not be reflected in the financial accounts to be presented on Thursday.

It means in effect that Fonterra achieved just around $400 million of its targeted $800 million debt reduction in the July 2019 financial year. But it does give the struggling co-operative a good start to the 2020 financial year.

DFE Pharma is a joint venture with Dutch co-operative FrieslandCampina. It had revenues in 2018 of $346 million and operating earnings of $100 million.  

The stake's being sold to funds managed by giant global private equity firm CVC Capital Partners.

In tandem with the release of its financial results on Thursday, Fonterra was set to announce its new strategy.

It has already given obvious hints of this by putting various assets outside of New Zealand up for review.

This was the statement Fonterra issued:

Fonterra today agreed the sale of its 50% share of DFE Pharma for NZ$633 million. The cash from this sale, along with proceeds from our other asset sales across the year – which includes the significant contribution from Tip Top – will give us over $1 billion available for debt reduction.

Fonterra CEO, Miles Hurrell, says “we set ourselves a tough initial target for debt reduction and we are pleased with the progress we are making. It’s an important milestone in our Co-op’s plan to lift our business performance.

“A year ago, we started a full portfolio review to re-evaluate every investment, major asset and partnership, to make sure they were still right for the Co-op.

“In March, we advised that we were reviewing our share of DFE Pharma, a 50% joint venture with Royal Friesland Campina. DFE Pharma was identified for sale due to the substantial capital required for its future growth.

“We are now at the end of that process and have sold our share of DFE Pharma to CVC Strategic Opportunities II, a fund managed by CVC Capital Partners, a leading private equity and investment advisory firm, managing approximately US$83 billion of assets in 73 companies worldwide,” Mr Hurrell says.

The $633 million sale to CVC Strategic Opportunities II is made up of a cash payment of $537 million, payable on completion of the sale, plus an interest-accruing vendor loan of $96 million, for a term of up to 15 years. Built into the deal is a potential additional payment of up to $44 million based on DFE’s performance over two years.

The sale is subject to receipt of regulatory approvals from competition authorities.

Mr Hurrell said that Fonterra was pleased to have secured a good sale price and will stay committed to the ongoing success of the DFE Pharma business through a long-term supply agreement and the interest-accruing vendor loan.

“A big part of the success of DFE Pharma has been the high-quality lactose produced by the team at Fonterra’s Kapuni site in Taranaki and it is a good outcome to be able to continue to supply this.

“This milestone, along with the significant inroads made in our capital and operational expenditure during FY19, makes for a good initial chapter in our business turn-around. It puts us on the right footing to deliver our new strategy and a sustainable lift in our performance.” says Mr Hurrell.

We welcome your help to improve our coverage of this issue. Any examples or experiences to relate? Any links to other news, data or research to shed more light on this? Any insight or views on what might happen next or what should happen next? Any errors to correct?

We welcome your comments below. If you are not already registered, please register to comment.

Remember we welcome robust, respectful and insightful debate. We don't welcome abusive or defamatory comments and will de-register those repeatedly making such comments. Our current comment policy is here.

11 Comments

Comment Filter

Highlight new comments in the last hr(s).

How much did they pay when they bought into DFE?

Sale to another overseas fund which will off load later at a better profit than Fonterra may be getting now ?
Will there be any restrictive clauses as to who it can be on sold to ? How about undesirable entities in undesirable countries ? Because that may affect how it is operated in NZ...
Who are the real owners of CVC ?

All very good questions, and here's mine "If tomorrows announcement was due to be 'good', would I be announcing this development, today?"

Reporting requirements of the NZX would mean they have to announce this today whether they like it or not... so I wouldn't read too much into the timing.

CVC is a British PE firm headquartered in Luxembourg - if that info doesn't raise red flags on murky fund contributions and money-grubbing dealings, nothing does.

Vulture fund ?

Interests associated with Jonkey wouldn't be far from the truth!!

The fire sale continues.

Anyone know what the carrying value of DFE is ?
No mention of that suggest not a large book profit ?

they still need to get out of the Chinese farms, that should be high on the agenda of things to be sold

Note that in terms of pure cashflow, it;s not $633m. It's $537m, with the rest dribbled in over 15 (!) years. $100m cashflow here, $100m cashflow there, pretty soon it adds up to Real Munny.....